On the public citation graph
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
0 signed · 882 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/ana.23982openalex-snapshot
Eteplirsen for the treatment of Duchenne muscular dystrophy
inferredcites →https://doi.org/10.1016/j.bcp.2008.11.005openalex-snapshot
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100
inferredcites →https://doi.org/10.1016/j.bcp.2009.04.013openalex-snapshot
Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2′-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN
inferredcites →https://doi.org/10.1016/j.celrep.2014.02.008openalex-snapshot
Peripheral Androgen Receptor Gene Suppression Rescues Disease in Mouse Models of Spinal and Bulbar Muscular Atrophy
inferredcites →https://doi.org/10.1016/j.coph.2005.07.001openalex-snapshot
Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers
inferredcites →https://doi.org/10.1016/j.ddstr.2013.04.002openalex-snapshot
Antisense therapies for cancer
inferredcites →https://doi.org/10.1016/j.neuron.2012.05.009openalex-snapshot
Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis
inferredcites →https://doi.org/10.1016/j.neuron.2014.03.001openalex-snapshot
Muscle Expression of Mutant Androgen Receptor Accounts for Systemic and Motor Neuron Disease Phenotypes in Spinal and Bulbar Muscular Atrophy
inferredcites →https://doi.org/10.1016/s0303-7207(03)00008-xopenalex-snapshot
PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat
inferredcites →https://doi.org/10.1016/s1359-6446(01)02123-7openalex-snapshot
Antisense Drug Technology: Principles, Strategies, and Applications
inferredcites →https://doi.org/10.1016/s1474-4422(13)70061-9openalex-snapshot
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
inferredcites →https://doi.org/10.1038/78475openalex-snapshot
Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis
inferredcites →https://doi.org/10.1038/nature11362openalex-snapshot
Targeting nuclear RNA for in vivo correction of myotonic dystrophy
inferredcites →https://doi.org/10.1038/nmat3765openalex-snapshot
Delivery materials for siRNA therapeutics
inferredcites →https://doi.org/10.1038/nsmb780openalex-snapshot
Kinetic analysis of the RNAi enzyme complex
inferredcites →https://doi.org/10.1056/nejmoa073108openalex-snapshot
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
inferredcites →https://doi.org/10.1073/pnas.142298199openalex-snapshot
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice
inferredcites →https://doi.org/10.1074/jbc.m311683200openalex-snapshot
Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs
inferredcites →https://doi.org/10.1089/108729002760070803openalex-snapshot
Pharmacokinetics and Tissue Distribution of a Peptide Nucleic Acid After Intravenous Administration
inferredcites →https://doi.org/10.1089/nat.2012.0371openalex-snapshot
Toxicological and Pharmacokinetic Properties of Chemically Modified siRNAs Targeting p53 RNA Following Intravenous Administration
inferredcites →https://doi.org/10.1089/nat.2013.0443openalex-snapshot
Characterization of Target mRNA Reduction Through In Situ RNA Hybridization in Multiple Organ Systems Following Systemic Antisense Treatment in Animals
inferredcites →https://doi.org/10.1093/nar/gkr089openalex-snapshot
Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes
inferredcites →https://doi.org/10.1093/nar/gkt725openalex-snapshot
Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS
inferredcites →https://doi.org/10.1093/nar/gku484openalex-snapshot
TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells
inferredcites →https://doi.org/10.1093/nar/gku531openalex-snapshot
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennaryN-acetyl galactosamine improves potency 10-fold in mice
inferredcites →https://doi.org/10.1111/j.1365-2125.2012.04469.xopenalex-snapshot
Clinical pharmacological properties of mipomersen ( K ynamro), a second generation antisense inhibitor of apolipoprotein B
inferredcites →https://doi.org/10.1124/dmd.106.012401openalex-snapshot
Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100
inferredcites →https://doi.org/10.1124/jpet.113.212407openalex-snapshot
Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl–Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates
inferredcites →https://doi.org/10.1126/scitranslmed.3001777openalex-snapshot
Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy
inferredcites →https://doi.org/10.1146/annurev.pharmtox.010909.105654openalex-snapshot
RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
inferredcites →https://doi.org/10.1158/1078-0432.ccr-07-1310openalex-snapshot
A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-10-1932openalex-snapshot
Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study
inferredcites →https://doi.org/10.1172/jci25424openalex-snapshot
Antisense oligonucleotide therapy for neurodegenerative disease
inferredcites →https://doi.org/10.1201/9780849387951-14openalex-snapshot
Basic Principles of the Pharmacokinetics of Antisense Oligonucleotide Drugs
inferredcites →https://doi.org/10.1201/9780849387951-19openalex-snapshot
Pharmacokinetic/Pharmacodynamic Properties of Phosphorothioate 2-O-(2-Methoxyethyl)- Modified Antisense Oligonucleotides in Animals and Man
inferredcites →https://doi.org/10.1201/9780849387951-7openalex-snapshot
Mechanisms of Antisense Drug Action, an Introduction
inferredcites →https://doi.org/10.1517/17425250902877680openalex-snapshot
Antisense oligonucleotide pharmacokinetics and metabolism
inferredcites →https://doi.org/10.1517/17425255.2013.737320openalex-snapshot
Clinical pharmacokinetics of second generation antisense oligonucleotides
inferredcites →https://doi.org/10.2337/diabetes.51.4.1028openalex-snapshot
Specific Inhibition of PTEN Expression Reverses Hyperglycemia in Diabetic Mice
inferredcites →https://doi.org/10.2337/diabetes.51.8.2405openalex-snapshot
Protein Tyrosine Phosphatase 1B Reduction Regulates Adiposity and Expression of Genes Involved in Lipogenesis
inferredcites →https://doi.org/10.2533/chimia.1996.168openalex-snapshot
Second Generation of Antisense Oligonucleotides: From Nuclease Resistance to Biological Efficacy in Animals
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4765473openalex-extracted
Tmprss2-Specific Antisense Oligonucleotides Inhibit Emerging Viruses Entry
inferred← citeshttps://doi.org/10.1001/jamaneurol.2016.2089openalex-snapshot
Synthetic Nucleic Acids and Treatment of Neurological Diseases
inferred← citeshttps://doi.org/10.1002/1873-3468.13742openalex-snapshot
Highly efficient gene silencing in mouse brain by overhanging‐duplex oligonucleotides via intraventricular route
inferred← citeshttps://doi.org/10.1002/9781119070153.ch5openalex-snapshot
Tissue Distribution, Metabolism, and Clearance
inferred← citeshttps://doi.org/10.1002/9781119070153.ch6openalex-snapshot
Hybridization‐Independent Effects
inferred← citeshttps://doi.org/10.1002/9781119692799.ch11openalex-snapshot
PROGRESS OF OLIGONUCLEOTIDE THERAPEUTICS TARGET TO RNA
inferred← citeshttps://doi.org/10.1002/9781119824701.ch13openalex-snapshot
Emerging Landscape of Therapeutic Oligonucleotide Delivery by Cell‐penetrating Peptides
inferred← citeshttps://doi.org/10.1002/9783527840458.ch9openalex-snapshot
Small Molecules That Degrade RNA
inferred← citeshttps://doi.org/10.1002/adtp.202400231openalex-snapshot
Unlocking the Potential of Chemically Modified Nucleic Acid Therapeutics
inferred← citeshttps://doi.org/10.1002/advs.75837openalex-snapshot
Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects
inferred← citeshttps://doi.org/10.1002/ange.201611914openalex-snapshot
Neue Modalitäten für schwierige Zielstrukturen in der Wirkstoffentwicklung
inferred← citeshttps://doi.org/10.1002/ange.202012330openalex-snapshot
RNA‐PROTACs: Degraders of RNA‐Binding Proteins
inferred← citeshttps://doi.org/10.1002/ange.202315768openalex-snapshot
Impact of the Core Chemistry of Self‐Assembled Spherical Nucleic Acids on their In Vitro Fate
inferred← citeshttps://doi.org/10.1002/ange.202409440openalex-snapshot
Accessing Therapeutically‐Relevant Multifunctional Antisense Oligonucleotide Conjugates Using Native Chemical Ligation
inferred← citeshttps://doi.org/10.1002/ange.202419996openalex-snapshot
Self‐Assembly and Biological Properties of Highly Fluorinated Oligonucleotide Amphiphiles
inferred← citeshttps://doi.org/10.1002/anie.201611914openalex-snapshot
New Modalities for Challenging Targets in Drug Discovery
inferred← citeshttps://doi.org/10.1002/anie.202012330openalex-snapshot
RNA‐PROTACs: Degraders of RNA‐Binding Proteins
inferred← citeshttps://doi.org/10.1002/anie.202315768openalex-snapshot
Impact of the Core Chemistry of Self‐Assembled Spherical Nucleic Acids on their In Vitro Fate
inferred← citeshttps://doi.org/10.1002/anie.202409440openalex-snapshot
Accessing Therapeutically‐Relevant Multifunctional Antisense Oligonucleotide Conjugates Using Native Chemical Ligation
inferred← citeshttps://doi.org/10.1002/anie.202419996openalex-snapshot
Self‐Assembly and Biological Properties of Highly Fluorinated Oligonucleotide Amphiphiles
inferred← citeshttps://doi.org/10.1002/bmc.4839openalex-snapshot
In vitro metabolism of 2′‐ribose unmodified and modified phosphorothioate oligonucleotide therapeutics using liquid chromatography mass spectrometry
inferred← citeshttps://doi.org/10.1002/cam4.1604openalex-snapshot
Chronic myelogenous leukemia on target
inferred← citeshttps://doi.org/10.1002/cbic.201800417openalex-snapshot
A Versatile and Convenient Synthesis of 34S‐Labeled Phosphorothioate Oligonucleotides
inferred← citeshttps://doi.org/10.1002/cbic.201900297openalex-snapshot
Observing an Antisense Drug Complex in Intact Human Cells by in‐Cell NMR Spectroscopy
inferred← citeshttps://doi.org/10.1002/cbic.202400908openalex-snapshot
Chondroitin Sulfate‐Coated Heteroduplex‐Molecular Spherical Nucleic Acids
inferred← citeshttps://doi.org/10.1002/chem.201701670openalex-snapshot
Towards Improved Oligonucleotide Therapeutics Through Faster Target Binding Kinetics
inferred← citeshttps://doi.org/10.1002/chem.201901077openalex-snapshot
Base‐Pairing Properties of Double‐Headed Nucleotides
inferred← citeshttps://doi.org/10.1002/chem.201903240openalex-snapshot
Introducing LNAzo: More Rigidity for Improved Photocontrol of Oligonucleotide Hybridization**
inferred← citeshttps://doi.org/10.1002/cnma.201600036openalex-snapshot
Progress in Biomedical Applications of Functionalized Nucleic Acid Nanodevices (NANDs)
inferred← citeshttps://doi.org/10.1002/cpdd.1154openalex-snapshot
Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses
inferred← citeshttps://doi.org/10.1002/cpdd.1454openalex-snapshot
A Phase 1, Single‐Dose Study to Evaluate the Pharmacokinetics and Safety of Bepirovirsen in Adults with Hepatic Impairment and Healthy Participants (B‐Assured)
inferred← citeshttps://doi.org/10.1002/cpdd.1518openalex-snapshot
Lack of Pharmacokinetic Drug–Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs
inferred← citeshttps://doi.org/10.1002/cpt.2531openalex-snapshot
Translational Approaches for Brain Delivery of Biologics via Cerebrospinal Fluid
inferred← citeshttps://doi.org/10.1002/ctm2.70314openalex-snapshot
Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease
inferred← citeshttps://doi.org/10.1002/ijch.202000021openalex-snapshot
Challenges in RNA Regulation in Huntington's Disease: Insights from Computational Studies
inferred← citeshttps://doi.org/10.1002/inmd.20230041openalex-snapshot
Nucleic acid drug and delivery techniques for disease therapy: Present situation and future prospect
inferred← citeshttps://doi.org/10.1002/jcb.28947openalex-snapshot
Inhibition of myeloid differentiation 1 specifically in colon with antisense oligonucleotide exacerbates dextran sodium sulfate‐induced colitis
inferred← citeshttps://doi.org/10.1002/jcp.30992openalex-snapshot
Long noncoding RNAs induced control of ferroptosis: Implications in cancer progression and treatment
inferred← citeshttps://doi.org/10.1002/jcph.2121openalex-snapshot
Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2′‐MOE and Phosphorothioate Modified Antisense Oligonucleotides
inferred← citeshttps://doi.org/10.1002/jcph.70034openalex-snapshot
Trends in First‐in‐Human Studies for Intrathecal Antisense Oligonucleotides: Insights From 2010 to 2024
inferred← citeshttps://doi.org/10.1002/jcph.70267openalex-snapshot
Pharmacokinetic/Pharmacodynamic Translation and Model‐Informed Drug Development for Oligonucleotide Therapeutics
inferred← citeshttps://doi.org/10.1002/jcph.70276openalex-snapshot
Clinical Pharmacology of Eplontersen, the First Approved GalNAc‐Conjugated Antisense Oligonucleotide
inferred← citeshttps://doi.org/10.1002/jcph.884openalex-snapshot
Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations
inferred← citeshttps://doi.org/10.1002/jcsm.13691openalex-snapshot
Targeting Drug Delivery System to Skeletal Muscles: A Comprehensive Review of Different Approaches
inferred← citeshttps://doi.org/10.1002/mas.21641openalex-snapshot
BIOANALYSIS AND BIOTRANSFORMATION OF OLIGONUCLEOTIDE THERAPEUTICS BY LIQUID CHROMATOGRAPHY‐MASS SPECTROMETRY
inferred← citeshttps://doi.org/10.1002/mds.27782openalex-snapshot
Antisense therapies for movement disorders
inferred← citeshttps://doi.org/10.1002/mds.28819openalex-snapshot
Gene Therapy for Polyglutamine Spinocerebellar Ataxias: Advances, Challenges, and Perspectives
inferred← citeshttps://doi.org/10.1002/med.21705openalex-snapshot
Modern approaches in gene therapy of motor neuron diseases
inferred← citeshttps://doi.org/10.1002/med.21718openalex-snapshot
Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era
inferred← citeshttps://doi.org/10.1002/mgg3.1405openalex-snapshot
Transcriptome sequencing identifies a noncoding, deep intronic variant in CLCN7 causing autosomal recessive osteopetrosis
inferred← citeshttps://doi.org/10.1002/mgg3.1603openalex-snapshot
Update of genetic variants in CEP120 and CC2D2A—With an emphasis on genotype‐phenotype correlations, tissue specific transcripts and exploring mutation specific exon skipping therapies
inferred← citeshttps://doi.org/10.1002/mus.26001openalex-snapshot
Making sense of antisense oligonucleotides: A narrative review
inferred← citeshttps://doi.org/10.1002/polb.24780openalex-snapshot
Melting thermodynamics of oligonucleic acids conjugated with relatively solvophobic linear polymers: A coarse‐grained molecular simulation study
inferred← citeshttps://doi.org/10.1002/psp4.12323openalex-snapshot
A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
inferred← citeshttps://doi.org/10.1002/psp4.13001openalex-snapshot
Development of a population pharmacokinetic model to characterize the pharmacokinetics of intrathecally administered tominersen in cerebrospinal fluid and plasma
inferred← citeshttps://doi.org/10.1002/psp4.13160openalex-snapshot
Population pharmacokinetics of imetelstat, a first‐in‐class oligonucleotide telomerase inhibitor
inferred← citeshttps://doi.org/10.1002/psp4.70108openalex-snapshot
Modeling and Simulation Identifies Endocytosis Uptake Rate and Fraction Unbound as Important Predictors of Oligonucleotide Pharmacokinetics
inferred← citeshttps://doi.org/10.1002/rcm.10033openalex-snapshot
Optimisation of Heated Electrospray Ionisation Parameters to Minimise In‐Source Generated Impurities in the Analysis of Oligonucleotide Therapeutics
inferred← citeshttps://doi.org/10.1002/slct.202302253openalex-snapshot
Synthesis of Pyrimidine Modified Seleno‐DNA as a Novel Approach to Antisense Candidate
inferred← citeshttps://doi.org/10.1002/slct.73805openalex-snapshot
Aptamer‐Conjugated Nanoparticles: A New Frontier in Gene Delivery for Effective Cancer Treatment
inferred← citeshttps://doi.org/10.1002/smll.201900055openalex-snapshot
Development of “CLAN” Nanomedicine for Nucleic Acid Therapeutics
inferred← citeshttps://doi.org/10.1002/smll.202407742openalex-snapshot
Photochemical Stabilization of Self‐Assembled Spherical Nucleic Acids
inferred← citeshttps://doi.org/10.1002/smll.202506812openalex-snapshot
Recent Advances in Lipid Nanoparticles: Nucleic Acid Therapeutics and Targeting Strategies
inferred← citeshttps://doi.org/10.1002/trc2.70165openalex-snapshot
Tau biology, biomarkers, and therapeutics
inferred← citeshttps://doi.org/10.1002/wnan.1606openalex-snapshot
Insight into the siRNA transmembrane delivery—From cholesterol conjugating to tagging
inferred← citeshttps://doi.org/10.1002/wrna.1703openalex-snapshot
Antisense oligonucleotide: A promising therapeutic option to beat COVID ‐19
inferred← citeshttps://doi.org/10.1007/978-1-0716-0771-8_11openalex-snapshot
Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitro
inferred← citeshttps://doi.org/10.1007/978-1-0716-0771-8_5openalex-snapshot
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
inferred← citeshttps://doi.org/10.1007/978-1-0716-0771-8_9openalex-snapshot
Tips for Successful lncRNA Knockdown Using Gapmers
inferred← citeshttps://doi.org/10.1007/978-1-0716-1581-2_10openalex-snapshot
In Vitro Silencing of lncRNAs Using LNA GapmeRs
inferred← citeshttps://doi.org/10.1007/978-1-0716-2010-6_25openalex-snapshot
Preclinical Safety Assessment of Therapeutic Oligonucleotides
inferred← citeshttps://doi.org/10.1007/978-1-0716-4554-3_18openalex-snapshot
Drug Delivery in Rare Diseases: Orphan Drugs and Therapies
inferred← citeshttps://doi.org/10.1007/978-1-0716-4742-4_3openalex-snapshot
Chemical Modifications in Nucleic Acid Therapeutics
inferred← citeshttps://doi.org/10.1007/978-1-0716-5272-5_5openalex-snapshot
Detection of Unlabeled Oligonucleotides in FFPE Tissue Sections Using Automated miRNAscope Assays
inferred← citeshttps://doi.org/10.1007/978-1-0716-5476-7_10openalex-snapshot
Development of Antisense Oligonucleotide Gapmers for Amyotrophic Lateral Sclerosis
inferred← citeshttps://doi.org/10.1007/978-1-0716-5476-7_12openalex-snapshot
LncRNA Knockdown Using Gapmer Antisense Oligonucleotides
inferred← citeshttps://doi.org/10.1007/978-1-0716-5476-7_13openalex-snapshot
Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitro
inferred← citeshttps://doi.org/10.1007/978-1-0716-5476-7_16openalex-snapshot
Gapmer and Mixmer Antisense Oligonucleotides to Selectively Suppress the Mutant Allele in COL6A Genes in Dominant Ullrich Congenital Muscular Dystrophy
inferred← citeshttps://doi.org/10.1007/978-1-0716-5476-7_18openalex-snapshot
Tissue Pharmacokinetics of Antisense Oligonucleotides
inferred← citeshttps://doi.org/10.1007/978-1-0716-5476-7_5openalex-snapshot
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
inferred← citeshttps://doi.org/10.1007/978-1-4939-7652-2_16openalex-snapshot
Loading of Extracellular Vesicles with Hydrophobically Modified siRNAs
inferred← citeshttps://doi.org/10.1007/978-1-4939-7825-0_23openalex-snapshot
Translating Antisense Technology into a Treatment for Huntington’s Disease
inferred← citeshttps://doi.org/10.1007/978-1-4939-9092-4_5openalex-snapshot
Synthetic Oligonucleotides in SPECT/CT In Vivo Imaging: Chemical Modifications, In111 Complex Formation, Incorporation into Drug Delivery Systems
inferred← citeshttps://doi.org/10.1007/978-1-4939-9670-4_18openalex-snapshot
Studying the Biotransformation of Phosphorothioate-Containing Oligonucleotide Drugs by LC-MS
inferred← citeshttps://doi.org/10.1007/978-1-4939-9670-4_19openalex-snapshot
ADME: Assessing Pharmacokinetic–Pharmacodynamic Parameters of Oligonucleotides
inferred← citeshttps://doi.org/10.1007/978-3-030-19966-1_7openalex-snapshot
RNA Therapeutics: How Far Have We Gone?
inferred← citeshttps://doi.org/10.1007/978-3-030-45493-7_3openalex-snapshot
IPSC Models of Chromosome 15Q Imprinting Disorders: From Disease Modeling to Therapeutic Strategies
inferred← citeshttps://doi.org/10.1007/978-3-030-72702-4_16openalex-snapshot
Development of RNA-Based Medicine for Colorectal Cancer: Current Scenario
inferred← citeshttps://doi.org/10.1007/978-3-030-73317-9_80-1openalex-snapshot
The Use of Göttingen Minipigs in Juvenile Studies
inferred← citeshttps://doi.org/10.1007/978-3-031-30023-3_13openalex-snapshot
Oligonucleotides and mRNA Therapeutics
inferred← citeshttps://doi.org/10.1007/978-3-031-30023-3_6openalex-snapshot
Pharmacokinetics and Pharmacodynamics of Therapeutic Proteins and Nucleic Acids
inferred← citeshttps://doi.org/10.1007/978-3-031-35529-5_80openalex-snapshot
The Use of Göttingen Minipigs in Juvenile Studies
inferred← citeshttps://doi.org/10.1007/978-3-031-39558-1_20openalex-snapshot
Principles and Targets Underlying Spinal Analgesia
inferred← citeshttps://doi.org/10.1007/978-981-10-4310-9_9openalex-snapshot
Specific Increase of Protein Levels by Enhancing Translation Using Antisense Oligonucleotides Targeting Upstream Open Frames
inferred← citeshttps://doi.org/10.1007/978-981-16-1313-5_19-1openalex-snapshot
Mesyl Phosphoramidate Oligonucleotides: A New Promising Type of Antisense Agents
inferred← citeshttps://doi.org/10.1007/978-981-16-1313-5_96-1openalex-snapshot
Targeting RNA with Small Molecules
inferred← citeshttps://doi.org/10.1007/978-981-19-9776-1_19openalex-snapshot
Mesyl Phosphoramidate Oligonucleotides: A New Promising Type of Antisense Agents
inferred← citeshttps://doi.org/10.1007/978-981-19-9776-1_96openalex-snapshot
Targeting RNA with Small Molecules
inferred← citeshttps://doi.org/10.1007/s00115-020-00882-4openalex-snapshot
Genselektive Therapieansätze bei der Huntington-Krankheit
inferred← citeshttps://doi.org/10.1007/s00115-021-01224-8openalex-snapshot
[Disease-modifying treatment approaches in Huntington disease : Past and future].
inferred← citeshttps://doi.org/10.1007/s00204-021-03062-8openalex-snapshot
Nephrotoxic antisense oligonucleotide SPC5001 induces kidney injury biomarkers in a proximal tubule-on-a-chip
inferred← citeshttps://doi.org/10.1007/s00216-015-9266-1openalex-snapshot
Development of a method based on ultra high performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry for studying the in vitro metabolism of phosphorothioate oligonucleotides
inferred← citeshttps://doi.org/10.1007/s00216-020-02878-0openalex-snapshot
Studying in vitro metabolism of the first and second generation of antisense oligonucleotides with the use of ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry
inferred← citeshttps://doi.org/10.1007/s00216-026-06370-zopenalex-snapshot
Chemical cleavage coupled with LCMS to report on the true diastereomeric distributions of phosphorothioate linkages in gapmer ASO
inferred← citeshttps://doi.org/10.1007/s00253-017-8671-0openalex-snapshot
Advances in therapeutic bacterial antisense biotechnology
inferred← citeshttps://doi.org/10.1007/s00262-019-02438-1openalex-snapshot
A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression
inferred← citeshttps://doi.org/10.1007/s00415-018-9076-4openalex-snapshot
Spinocerebellar ataxia: an update
inferred← citeshttps://doi.org/10.1007/s10048-026-00887-2openalex-snapshot
Gene therapy for huntington’s disease: advances, challenges, and future perspectives
inferred← citeshttps://doi.org/10.1007/s10928-017-9505-5openalex-snapshot
Population pharmacokinetics and pharmacodynamics of IONIS-GCGRRx, an antisense oligonucleotide for type 2 diabetes mellitus: a red blood cell lifespan model
inferred← citeshttps://doi.org/10.1007/s10928-021-09761-0openalex-snapshot
A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration
inferred← citeshttps://doi.org/10.1007/s10928-025-09980-9openalex-snapshot
Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokinetics
inferred← citeshttps://doi.org/10.1007/s11033-020-05609-xopenalex-snapshot
Emerging role of long non-coding RNAs in cancer chemoresistance: unravelling the multifaceted role and prospective therapeutic targeting
inferred← citeshttps://doi.org/10.1007/s11095-021-03118-5openalex-snapshot
Pharmacokinetic/Pharmacodynamic Modeling of a Cell-Penetrating Peptide Phosphorodiamidate Morpholino Oligomer in mdx Mice
inferred← citeshttps://doi.org/10.1007/s11095-022-03433-5openalex-snapshot
CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood–Brain Barrier and Towards Specific Cellular Targeting
inferred← citeshttps://doi.org/10.1007/s11095-026-04034-2openalex-snapshot
Targeted Gene Therapy for Mutated H-ras and C-raf.1 Genes Exhibited Variable Efficacy in Inhibiting Hepatocellular Carcinoma in Rats: A Mechanistic Approach
inferred← citeshttps://doi.org/10.1007/s11481-021-09983-6openalex-snapshot
Intrathecal Administration of an Anti‐nociceptive Non-CpG Oligodeoxynucleotide Reduces Glial Activation and Central Sensitization
inferred← citeshttps://doi.org/10.1007/s11626-026-01154-2openalex-snapshot
Development of ARL4C antisense oligonucleotide with reduced off-target effects and enhanced efficacy as an anti-cancer drug
inferred← citeshttps://doi.org/10.1007/s11883-016-0609-yopenalex-snapshot
Targeting ApoC-III to Reduce Coronary Disease Risk
inferred← citeshttps://doi.org/10.1007/s12013-024-01395-6openalex-snapshot
Recent Advances in RNA Interference-Based Therapy for Hepatocellular Carcinoma: Emphasis on siRNA
inferred← citeshttps://doi.org/10.1007/s12032-024-02450-1openalex-snapshot
Targeted gene therapy for cancer: the impact of microRNA multipotentiality
inferred← citeshttps://doi.org/10.1007/s12032-026-03308-4openalex-snapshot
Decoy oligonucleotide technology in cancer therapy: molecular mechanisms, challenges, and translational potential
inferred← citeshttps://doi.org/10.1007/s12072-026-11102-7openalex-snapshot
Safety, pharmacokinetics and antiviral activity of AHB‑137 in healthy volunteers and chronic hepatitis B patients: a phase 1a/1b study
inferred← citeshttps://doi.org/10.1007/s12274-018-2131-8openalex-snapshot
PEGylation of therapeutic oligonucletides: From linear to highly branched PEG architectures
inferred← citeshttps://doi.org/10.1007/s12274-024-6776-1openalex-snapshot
Therapeutic nucleic acids in regenerative medicine and tissue repair
inferred← citeshttps://doi.org/10.1007/s12672-025-03571-3openalex-snapshot
The functions of circular RNAs and long noncoding RNAs in cholangiocarcinoma
inferred← citeshttps://doi.org/10.1007/s13311-018-00696-yopenalex-snapshot
Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias
inferred← citeshttps://doi.org/10.1007/s13311-018-00702-3openalex-snapshot
Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond
inferred← citeshttps://doi.org/10.1007/s13311-019-00740-5openalex-snapshot
Nucleic Acid-Based Therapeutics Relevant to Neuroimmune Conditions
inferred← citeshttps://doi.org/10.1007/s13311-020-00891-wopenalex-snapshot
Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies
inferred← citeshttps://doi.org/10.1007/s13311-022-01247-2openalex-snapshot
Antisense Oligonucleotides for the Study and Treatment of ALS
inferred← citeshttps://doi.org/10.1007/s13670-020-00341-7openalex-snapshot
Antisense Oligonucleotide Therapeutics for Neurodegenerative Disorders
inferred← citeshttps://doi.org/10.1007/s40119-024-00353-wopenalex-snapshot
Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?
inferred← citeshttps://doi.org/10.1007/s40120-020-00210-7openalex-snapshot
Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies
inferred← citeshttps://doi.org/10.1007/s40121-024-00980-9openalex-snapshot
Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b Studies
inferred← citeshttps://doi.org/10.1007/s40259-018-0286-1openalex-snapshot
Oligonucleotide-Based Therapies for Inflammatory Bowel Disease
inferred← citeshttps://doi.org/10.1007/s40259-022-00519-9openalex-snapshot
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic
inferred← citeshttps://doi.org/10.1007/s40259-024-00644-7openalex-snapshot
Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases
inferred← citeshttps://doi.org/10.1007/s40259-025-00731-3openalex-snapshot
Lipid-Lowering RNA Therapeutics for Atherosclerotic Cardiovascular Disease Prevention: A State−of−the−Art Review
inferred← citeshttps://doi.org/10.1007/s40263-019-00695-3openalex-snapshot
Recent Advances in the Treatment of Huntington’s Disease: Targeting DNA and RNA
inferred← citeshttps://doi.org/10.1007/s40265-019-01153-6openalex-snapshot
Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities
inferred← citeshttps://doi.org/10.1016/b978-0-12-409547-2.12424-2openalex-snapshot
Current Progress and Future Prospects in Nucleic Acid Based Therapeutics
inferred← citeshttps://doi.org/10.1016/b978-0-12-804279-3.00004-6openalex-snapshot
Dosing, collection, and quality control issues in cerebrospinal fluid research using animal models
inferred← citeshttps://doi.org/10.1016/b978-0-12-813955-4.00017-9openalex-snapshot
Antisense oligonucleotide drugs for neurological and neuromuscular disease
inferred← citeshttps://doi.org/10.1016/b978-0-12-814470-1.00001-0openalex-snapshot
Therapeutic Oligonucleotides Against Cancer: Recent Approaches and New Perspectives
inferred← citeshttps://doi.org/10.1016/b978-0-12-815669-8.00006-3openalex-snapshot
MicroRNAs in diagnosis and therapeutics
inferred← citeshttps://doi.org/10.1016/b978-0-12-819666-3.00005-5openalex-snapshot
Tailoring drug and gene codelivery nanosystems for glioblastoma treatment
inferred← citeshttps://doi.org/10.1016/b978-0-12-820018-6.00018-1openalex-snapshot
Predictive and translational models for renal drug safety evaluation
inferred← citeshttps://doi.org/10.1016/b978-0-12-820472-6.00141-9openalex-snapshot
ADME of Biologicals and New Therapeutic Modalities
inferred← citeshttps://doi.org/10.1016/b978-0-12-821047-5.00017-8openalex-snapshot
Nucleic Acid Pharmaceutical Agents
inferred← citeshttps://doi.org/10.1016/b978-0-12-821567-8.00024-5openalex-snapshot
Role of microRNA therapy in presensitizing glioblastoma cells to temozolomide treatment
inferred← citeshttps://doi.org/10.1016/b978-0-12-822258-4.00010-9openalex-snapshot
Therapeutic strategies for modulating epigenetic mechanisms in cardiovascular disease
inferred← citeshttps://doi.org/10.1016/b978-0-323-71317-7.00011-1openalex-snapshot
Molecular and Genetic Therapies
inferred← citeshttps://doi.org/10.1016/b978-0-323-89774-7.00006-6openalex-snapshot
MicroRNA-based therapeutic strategies for chronic kidney disease and uremic cardiomyopathy
inferred← citeshttps://doi.org/10.1016/b978-0-323-90120-8.00006-xopenalex-snapshot
Clinical/surgical considerations
inferred← citeshttps://doi.org/10.1016/b978-0-323-90406-3.00005-1openalex-snapshot
Non-coding RNAs in human infectious diseases
inferred← citeshttps://doi.org/10.1016/b978-0-323-91865-7.00010-9openalex-snapshot
Nanovesicles for the delivery of siRNA
inferred← citeshttps://doi.org/10.1016/b978-0-323-95488-4.00161-3openalex-snapshot
Analytical Methods in Biotransformation Studies
inferred← citeshttps://doi.org/10.1016/b978-0-443-19041-4.00039-xopenalex-snapshot
Antisense oligonucleotide drugs for neurological and neuromuscular diseases
inferred← citeshttps://doi.org/10.1016/b978-0-443-33475-7.00009-3openalex-snapshot
Unraveling the mystery of treatment resistance in colorectal cancer
inferred← citeshttps://doi.org/10.1016/b978-0-443-33475-7.00011-1openalex-snapshot
Splicing-associated drug resistance in colorectal cancer: targeting splicing signatures
inferred← citeshttps://doi.org/10.1016/bs.armc.2017.07.003openalex-snapshot
The Chemistry of Oligonucleotide Delivery
inferred← citeshttps://doi.org/10.1016/bs.ircmb.2017.07.008openalex-snapshot
Alternative Splicing in Genetic Diseases: Improved Diagnosis and Novel Treatment Options
inferred← citeshttps://doi.org/10.1016/j.addr.2016.06.008openalex-snapshot
Peptides for nucleic acid delivery
inferred← citeshttps://doi.org/10.1016/j.addr.2020.09.012openalex-snapshot
Engineered tissues and strategies to overcome challenges in drug development
inferred← citeshttps://doi.org/10.1016/j.addr.2021.03.002openalex-snapshot
Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues
inferred← citeshttps://doi.org/10.1016/j.addr.2021.05.019openalex-snapshot
Nanomedicine-based delivery strategies for nucleic acid gene inhibitors in inflammatory diseases
inferred← citeshttps://doi.org/10.1016/j.addr.2021.114041openalex-snapshot
Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
inferred← citeshttps://doi.org/10.1016/j.addr.2021.114045openalex-snapshot
MicroRNAs and their delivery in diabetic fibrosis
inferred← citeshttps://doi.org/10.1016/j.addr.2023.114872openalex-snapshot
Development of nucleic acid medicines based on chemical technology
inferred← citeshttps://doi.org/10.1016/j.addr.2024.115354openalex-snapshot
Nanoassemblies designed for efficient nuclear targeting
inferred← citeshttps://doi.org/10.1016/j.addr.2026.115778openalex-snapshot
Bioconjugates for improved delivery of oligonucleotide therapeutics to the central nervous system
inferred← citeshttps://doi.org/10.1016/j.ajhg.2026.01.016openalex-snapshot
Enhanced muscle uptake of chemically optimized miR-23b antisense oligonucleotides as lead compounds for myotonic dystrophy type 1
inferred← citeshttps://doi.org/10.1016/j.ajps.2019.12.001openalex-snapshot
Enhanced lysosome escape mediated by 1,2-dicarboxylic-cyclohexene anhydride-modified poly-l-lysine dendrimer as a gene delivery system
inferred← citeshttps://doi.org/10.1016/j.antiviral.2016.07.004openalex-snapshot
Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection
inferred← citeshttps://doi.org/10.1016/j.antiviral.2017.10.022openalex-snapshot
Activity of nucleic acid polymers in rodent models of HBV infection
inferred← citeshttps://doi.org/10.1016/j.antiviral.2019.02.009openalex-snapshot
Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2018.09.040openalex-snapshot
Long intergenic noncoding RNAs in cardiovascular diseases: Challenges and strategies for physiological studies and translation
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2022.12.003openalex-snapshot
Targeting and delivery of microRNA-targeting antisense oligonucleotides in cardiovascular diseases
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2025.119114openalex-snapshot
Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA
inferred← citeshttps://doi.org/10.1016/j.bbcan.2015.06.008openalex-snapshot
The role of recent nanotechnology in enhancing the efficacy of radiation therapy
inferred← citeshttps://doi.org/10.1016/j.bbcan.2021.188584openalex-snapshot
Long non-coding RNAs: A view to kill ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.bbcan.2026.189676openalex-snapshot
The ER stress-autophagy axis in cancer-induced muscle wasting: Unveiling the IRE1α/XBP1 pathway as a therapeutic target
inferred← citeshttps://doi.org/10.1016/j.bcp.2018.11.013openalex-snapshot
Comparison of different chemically modified inhibitors of miR-199b in vivo
inferred← citeshttps://doi.org/10.1016/j.bcp.2020.114196openalex-snapshot
Antisense drug discovery and development technology considered in a pharmacological context
inferred← citeshttps://doi.org/10.1016/j.bioactmat.2022.05.016openalex-snapshot
Selection and identification of a novel ssDNA aptamer targeting human skeletal muscle
inferred← citeshttps://doi.org/10.1016/j.biocel.2019.03.009openalex-snapshot
Antisense oligonucleotide therapies for Amyotrophic Lateral Sclerosis: Existing and emerging targets
inferred← citeshttps://doi.org/10.1016/j.biopha.2016.12.118openalex-snapshot
Dermal/transdermal delivery of small interfering RNA and antisense oligonucleotides- advances and hurdles
inferred← citeshttps://doi.org/10.1016/j.biopha.2024.116737openalex-snapshot
Efficient systemic CNS delivery of a therapeutic antisense oligonucleotide with a blood-brain barrier-penetrating ApoE-derived peptide
inferred← citeshttps://doi.org/10.1016/j.biopha.2024.117587openalex-snapshot
Therapeutic oligonucleotide ASC1R shows excellent tolerability and remarkable efficacy in reducing SARS-CoV-2 mRNA levels in C57BL/6 mice
inferred← citeshttps://doi.org/10.1016/j.biopha.2026.119808openalex-snapshot
Therapeutic potential of antisense oligonucleotides in hematological malignancies
inferred← citeshttps://doi.org/10.1016/j.biotechadv.2026.108862openalex-snapshot
RNA therapeutics 2.0: Expanding the landscape from mRNA vaccines to splicing modulators and beyond
inferred← citeshttps://doi.org/10.1016/j.bmcl.2015.08.019openalex-snapshot
Solid-phase synthesis of 5′-triantennary N-acetylgalactosamine conjugated antisense oligonucleotides using phosphoramidite chemistry
inferred← citeshttps://doi.org/10.1016/j.bmcl.2016.05.084openalex-snapshot
Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes
inferred← citeshttps://doi.org/10.1016/j.bmcl.2019.04.030openalex-snapshot
Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges
inferred← citeshttps://doi.org/10.1016/j.canlet.2022.215618openalex-snapshot
A feedforward circuit between KLF5 and lncRNA KPRT4 contributes to basal-like breast cancer
inferred← citeshttps://doi.org/10.1016/j.cbpa.2018.05.018openalex-snapshot
Therapeutic strategies for targeting neurodegenerative protein misfolding disorders
inferred← citeshttps://doi.org/10.1016/j.cell.2017.07.010openalex-snapshot
Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9
showing the first 200 of 840 · page through all 840
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.